Bristol-Myers Squibb

Could proxy advisors sway investors to vote ‘no’ on BMS-Celgene merger?
Fierce Pharma
Thu, 03/21/19 - 12:17 pm
Bristol-Myers Squibb
Celgene
investors
M&A
Bristol-Myers and Starboard Value spar over $74B Celgene buyout as shareholder vote looms
Endpoints
Tue, 03/19/19 - 10:37 am
Bristol-Myers Squibb
Starboard
Celgene
M&A
Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
Motley Fool
Fri, 03/15/19 - 11:55 pm
M&A
Bristol-Myers Squibb
Celgene
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Wed, 03/13/19 - 10:13 am
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the company since '17
Endpoints
Tue, 03/12/19 - 07:35 pm
Bristol-Myers Squibb
Celgene
Giovanni Caforio
M&A
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Mon, 03/11/19 - 10:25 pm
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
Does Bristol-Myers have a plan B if activists scuttle its Celgene buy?
Fierce Pharma
Mon, 03/11/19 - 10:09 pm
Bristol-Myers Squibb
Celgene
M&A
It’s what Bristol-Myers execs aren’t saying that makes one key analyst wonder about a potential buyout offer, looming Opdivo data and Plan B
Endpoints
Mon, 03/11/19 - 10:07 am
Bristol-Myers Squibb
Celgene
M&A
Opdivo
Bristol-Myers urges shareholders in open letter to support $74 billion Celgene deal amid resistance
CNBC
Wed, 03/6/19 - 09:53 am
Bristol-Myers Squibb
M&A
Celgene
The Bristol-Myers–Squibb Deal May No Longer Be a Sure Thing, but It Will Still Likely Happen
Barron's
Sat, 03/2/19 - 12:39 pm
M&A
Bristol-Myers Squibb
Celgene
Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington
Xconomy
Wed, 02/27/19 - 07:21 pm
Bristol-Myers Squibb
Celgene
M&A
Wellington
CytomX R&D day reveals Probody toxicity, chopped BMS deal
BioCentury
Tue, 02/26/19 - 06:32 pm
CytomX Therapeutics
CD166
Bristol-Myers Squibb
probodies
Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers
Yahoo/Guru Focus
Sun, 02/24/19 - 11:36 pm
M&A
Merck
Biogen
Biomarin
Eli Lilly
Bristol-Myers Squibb
The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress
Stat
Thu, 02/21/19 - 12:41 pm
drug pricing
US Congress
Donald Trump
Richard Gonzalez
AbbVie
Ken Frazier
Merck
JNJ
Jennifer Taubert
Olivier Brandicourt
Sanofi
Pascal Soriot
AstraZeneca
Giovanni Caforio
Bristol-Myers Squibb
Albert Bourla
Pfizer
Starboard plots board coup after buying into Bristol-Myers in lead-up to Celgene buyout vote
Endpoints
Thu, 02/21/19 - 12:28 pm
Jeff Smith
Starboard
M&A
Celgene
Bristol-Myers Squibb
Using Bristol-Myers’ popular leukemia drug to improve anti-PD-1 cancer immunotherapy
Fierce Biotech
Wed, 02/20/19 - 08:00 pm
cancer
Cedars Sinai
Bristol-Myers Squibb
Sprycel
anti-PD-L1
Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
Yahoo/Reuters
Sat, 02/16/19 - 03:53 pm
Nektar
Bristol-Myers Squibb
bladder cancer
NKTR-214
Opdivo
Starboard gauges Bristol-Myers shareholder support for Celgene deal
Yahoo/Reuters
Sat, 02/16/19 - 03:39 pm
Bristol-Myers Squibb
Celgene
M&A
Starboard
shareholders
Exelixis Proves Being Second Can Work Out Well
Motley Fool
Wed, 02/13/19 - 05:04 pm
Exelixis
Bristol-Myers Squibb
Cabometyx
kidney cancer
Bladder cancer readout sees Nektar shares hit
Fierce Biotech
Tue, 02/12/19 - 11:36 am
Nektar Therapeutics
bladder cancer
NKTR-214
Opdivo
Bristol-Myers Squibb

Pages